Summary Report of Consolidated Financial Results
For the Six Months Period ended September 30, 2010

November 10, 2010
Company name: NIPRO CORPORATION
TSE/OSE–1st section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Minoru Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06) 6372-2331
Filling date of quarterly reporting: November 12, 2010
Payment date of cash dividends: December 9, 2010
Supplemental material on quarterly reporting: None
Presentation on quarterly results: Yes (for institutional investors and analysts)(Note: Amounts are truncated to one million yen)
1. Consolidated results for the Six months ended September 30, 2010 (From April 1, 2010 to September 30, 2010)(1) Consolidated results of operations(Note: % of change from the same period a year ago)
Net Sales

Operating Income

Millions of yen%

Millions of yen

94,64087,435

8.2
1.0

9,031
9,261

6 months ended Sept. 30,2010
6 months ended Sept. 30,2009

Earnings per Share
6 months ended Sept. 30,2010
6 months ended Sept. 30,2009

Ordinary Income%

Millions of yen

(2.5)
33.2

5,470
6,999

Net Income%

Millions of yen(21.8)
0.9

2,469
3,494

%

(29.3)
2.7

Diluted Earnings per share

Yen

Yen

38.94
55.09

35.13
-

(2) Consolidated Financial Position

Total Assets

Net Assets

Millions of yen

Millions of yen

385,070
383,396

113,586
116,070

6 months ended Sept. 30,2010
Year ended March 31, 2010

Note: Equity 6 months ended Sept. 30, 2010 111,552 million yen

Net Assets per
Share

Equity Ratio
%

Yen

29.0
29.8

Year ended March 31, 2010

1,758.87
1,802.33
114,309 million yen

2. Dividends
Annual dividends per shareFirstquarter

Secondquarter
Yen-

Year ended March 31, 2010
Year ending March 31, 2011
Year ending March 31, 2011
(Forecast)Thirdquarter
Yen

Year-end
Dividends
Yen

Yen

23.50
18.50

Annualdividends
Yen

-

29.50

53.00

-

22.50

41.00

Note: Whether the forecast of cash dividends has been revised in the current quarter or not: Yes

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2011 (From April 1, 2010 to March 31, 2011)(Note: The % display shows increase/decrease ratio against the year ended March 31, 2010)
Operating
Ordinary
Earnings
Net Sales
Net Income
per Share
IncomeIncomeYear ending March 31, 2011

Millionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Yen

200,000

12.5

17,200(4.9)

12,100(18.8)

4,950(31.7)

78.05

Note: Whether the forecast of consolidated financial results has been revised in the current quarter or not: Yes

4. Others (For details, please refer to “2. Other information” on page 4 of attached documents.)(1) Change in significant subsidiaries during the current period: No(Note) Change in specified subsidiaries during the period that caused a change in the scope of consolidation(2) Adoption of accounting treatments simplified or unique for preparation: Yes(Note) Adoption of accounting treatments simplified and unique for preparation of quarterly consolidated financial
statements(3) Changes in accounting principles, procedures or presentation for consolidated financial statements[1] Changes by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No(Note) Changes in significant accounting principles, procedure and presentation which are to be stated in “Change insignificant matter of basis of preparation for consolidated financial statements”(4) Issued shares (Common stock)[1] Number of issued shares at end of the period (Including treasury stock):
6 months ended Sept. 30, 2010: 63,878,505 sharesYear ended March 31, 2010: 63,878,505 shares[2] Number of treasury stock at end of the period:
6 months ended Sept. 30, 2010: 455,987 sharesYear ended March 31, 2010: 455,328 shares[3] Average number of shares during the period:
6 months ended Sept. 30, 2010: 63,422,929 shares
6 months ended Sept. 30, 2009: 63,427,015 shares*Information regarding the quarterly review procedure
This report is exempt from quarterly review procedure based on the Financial Instruments and Exchange Act. It is under thereview procedure process at the time of disclosure of this report.

*Disclaimer regarding projection information including appropriate use of forecasted financial results, and other special notes
The projection figures shown above are based on information that was available at the time of preparation and may containcertain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstancesand other developments. More information concerning these forecasts can be found in P.4 “1. Qualitative information for thesix months period ended September 30, 2010, (3) Qualitative information concerning forecast of consolidated financial results”
in the attachments.

Table of contents

1. Qualitative information for the six months period ended Sept. 30, 2010
(1)Qualitative information concerning consolidated financial results(2)Qualitative information on the consolidated financial position(3)Qualitative information concerning forecast of consolidated financial results

P.2
P.2
P.3
P.4

2. Other information(1)Overview of changes in significant consolidated subsidiaries(2)Overview of accounting treatments simplified or unique for preparation(3)Overview of changes in accounting principles, procedures, and disclosure for preparation

P.4
P.4
P.4
P.5

3. Consolidated financial statements(1)Quarterly consolidated balance sheets(2)Quarterly consolidated statements of income(3)Quarterly consolidated statements of cash flows(4)Notes related to going concern(5)Segment information(6)Notes to statements of shareholders’ equity, if having significant variation

P.6
P.6
P.8
P.9
P.11
P.11
P.14

-1-

1. Qualitative information for the six months period ended September 30, 2010
(1) Qualitative information concerning consolidated financial results
During the six months period ended September 30, 2010, despite the emerging countries could enjoy steadyeconomic progress, the whole world economy could not take such trends as granted because there were
slowdown in the U.S. and European economies. The Japanese economy could avert a recession thanks to theincrease in exports to Asia, rush demand of eco-car and demand effect by the scorching summers, but there
still remains the uncertainty about the recovery due to the concern about the sharp appreciation of yen andcontinuous decline in stock prices.
Under such circumstances, we aimed to expand sales and production and improve production efficiency andpromoted manufacturing in each location on the basis of local production for local consumption, all of which will
help us improve our business performance.
Therefore, we grew each business and the consolidated sales in this six months period increased 8.2%
compared with the same period a year ago to 94,640 million yen.
As for the profit, consolidated operating income decreased 2.5% compared with the same period a year ago
to 9,031 million yen due to the increase of selling, general and administrative expenses. Ordinary income
decreased 21.8% compared with the same period a year ago to 5,470 million yen due to the increase of
non-operating expenses.Net income decreased 29.3% compared with the same period a year ago to 2,469
million yen.
The overviews of the results by segment in the current period are as follows.
[1] Medical businessOn the domestic side of medical business, while continuously taken the policy on reduction of medical cost,the medical fee scheme in April 2010 became the upwardly-revised as a whole for the first time in 10 years.
However, official reimbursement price of drug and special treatment materials was reduced 1.36% and ourbusiness and market conditions remained severe. Under such circumstances, we have enlarged sales entities
and improved sales efficiency, aiming to expand our market share aggressively.
Sales grew greatly in vascular-related products (such as blood-clot trapping catheters, coronary artery stentand angiographic kit). In addition, sales of high-value-added products which can prevent malpractice andreduce infection risks, enteral alimentation-related products, dialysis related products (such as blood tube anddialysis solution) and testing-related products like glucose analysis device grew steadily and made a profit.
On the international side of the business, we had great impact by abrupt appreciation of Japanese yen
against the U.S. dollar and Euro. However, we continued to promote active sales promotion by strengthening
our direct selling system in Asian and Chinese market where the economy is significantly growing, and tostrengthen the community-based sales promotion in Latin American and European market so as to increase
the sales amount.
Sales grew greatly in diabetic-related products, as well as the sales in dialysis-related product (such as
dialysis machine and blood tube) increased steadily by means of our active sales promotions in the dialysis
market such as in China
As a result, net sales of the business were 63,866 million yen.
[2] Pharmaceutical businessIn pharmaceutical business, we can divide into two categories; one is generic drug business whose mission isto provide low price and high quality drugs, and the other is contract manufacturing business where we havecapacities to produce various drugs and to offer high value added solutions against customer needs.
On the sales of generic drug, under governmental policy calling for the dissemination of generic products‘generic drug share in quantity shall be expanded more than 30% until year 2012.’, the raising up of additional
points against dispensing has been implemented. Thus, while the market is in underlying expansion, we haveproactively promoted order increasing in sales of oral drug and drug for external use, including sales promotion
to dispensing pharmacy group. In addition, injectable drug sales of our main product grew steadily as a result-2-

of our detailed information service mainly to the hospitals subjected to the DPC system (Diagnostic Procedure
Combination; comprehension payment system of medical cost for acute hospitalization). Though we could not
avoid the sales decrease by drug price revision (scheduled biyearly), we registered significant sales growth atlast, compared to the same period of the prior year.
On the sales of contract manufacturing business, the sales resulted in exceeding prior year’s results byfocusing on getting contracts in oral drug sales, on top of injectable drug sales, since one of the biggest oral
drug plant in Japan was completed two years ago, and leaded by starting sell-in of new oral drugs andproduction lines for steroidal and penem drugs.
As a result, net sales of this business were 18,808 million yen.
[3] Glass & Materials businessIn the field of glass materials, the sales of glass tube for pharmaceutical purpose performed steady as whole
thanks to the increase demands of glass bottles for vaccine in the field of glass tube for glass bottles, though
the domestic demands in glass tube for pharmaceutical purpose decreased. Furthermore, we established thebusiness of glass for pharmaceutical purpose in China and India and started the operation. The export of glass
for thermos bottles had showed the trend of recovery but the demands decreased at last due to the sharp
appreciation of the yen. As for the sales of glass for lighting purposes, the sales of glass tube for electric lamp
increased thanks to the good condition in domestic production for automobile, on the other hand the sales ofglass tube for backlights decreased under the influence of penetration of LED products.
In the filed of other pharmaceutical container, the sales of rubber stopper for pharmaceutical use and glass
container for combination products (injectable lit products) increased as well as the sales of bags for
antimicrobial agent and member of pre-filled syringe increased steadily, based on our plastics, metal andrubber processing technologies.
As for the medicinal preparation and administration related device, we worked on joint development withpharmaceutical companies and advance unique development for productization so as to meet the diverse
needs. Furthermore, we have promoted contract manufacturing and development cooperating with domestic
and foreign pharmaceutical companies in general life cycle management of pharmaceuticals entering thedevelopment of combination products, systematization for self-injection and modification of dosage form in theview.
As a result, net sales of this business were 11,754 million yen.
[4] Other businessIn the other business, the sales from real estate rental income were 212 million yen.
(2) Qualitative information on the consolidated financial position[1] Analysis concerning the conditions of assets, liabilities and net assets
Total assets increased 1,673 million yen from the end of the previous period to 385,070 million yen. Current
assets increased 3,801 million yen and noncurrent assets decreased 2,128 million yen. Main reason for theincrease in current assets was that notes and accounts receivable-trade increased 2,582 million yen andmerchandise and finished goods increased 2,502 million yen. Main reason for the decrease in noncurrent
assets was that investment securities decreased 20,852 million yen.
Total liabilities increased 4,157 million yen to 271,483 million yen. Current liabilities decreased 1,198 million
yen and noncurrent liabilities increased 5,356 million yen. Current liabilities decreased mainly due to thedecrease of 10,000 million yen in commercial papers and main reason for the increase in noncurrent liabilities
was that long-term loans payable increased 6,748 million yen.
Net assets decreased 2,484 million yen to 113,586 million yen from the end of the previous period.
Shareholders’ equity increased 597 million yen and valuation and translation adjustments decreased 3,354
million yen.

-3-

[2] Analysis concerning the conditions of cash flows
The ending balance of cash and cash equivalents in the period under review decreased 3,559 million yen to52,628 million yen.
The conditions and main factors of each cash flow during the period under review were as follows.
(Cash flows from operating activities)
Net cash provided by operating activities was 9,583 million yen. The main accounts of cash inflow wereincome before income taxes and minority interests, 5,612 million yen, depreciation and amortization, 9,319
million yen. The main accounts of cash outflow were increase of inventories, 4,019 million yen, and payment ofcorporate income tax, 4,654 million yen.
(Cash flows from investing activities)
Net cash used in investing activities was 12,676 million yen. The main account of cash outflow werepurchase of investment securities 2,820 million yen and purchase of noncurrent assets 9,214 million yen.
(Cash flows from financing activities)
Net cash used in investing activities was 1,735 million yen. The main accounts of cash inflow were proceedsfrom long-term loans payable, 20,809 million yen. The main accounts of cash outflow were decrease incommercial papers, 10,000 million yen, and repayment of long-term loans payable, 10,157 million yen.
(3)Qualitative information concerning forecast of consolidated financial results
In the world economy in the future, U.S. economy is expected to recover gradually, on the other hand
economic activities in emerging countries and resource-rich country may bring about radical change in theworld economy. In the Japanese economy, impact of decreasing demands by the shrinking and aging
population and sharp appreciation of the yen will remain the business environment more severe.
Under such condition we aim to expand sales and production and improve production efficiency, and promote
manufacturing in each location on the basis of local production for local consumption so as to improve ourbusiness performance.
As for the forecast of consolidated financial results, we revised the forecast of consolidated financial results
for the fiscal year 2010(Year ending March 31, 2011) which was published May 14, 2010, in accordance with
our recent business performance.
2. Other information(1)Overview of changes in significant subsidiaries
N/A(2) Overview of accounting treatments simplified or unique for preparation[1] Simplified accounting procedures
1) Calculation of estimated impairment for general receivables
As it was accepted that there was no significant change between the actual rate or index of bad debts accrual
calculated at the end of the current quarterly consolidated accounting period and at the end of the previous
consolidated accounting year, the later rate or index was utilized for estimation of impairment of general
receivables.
2) Calculation method for depreciation of noncurrent assets
The noncurrent assets depreciated in declining balance method were calculated by prorating the depreciation
amount in the consolidated accounting year.

-4-3) Deferred tax assets and liabilities
As for the judgment of collectability of deferred tax assets, the forecasted financial results and tax planning
used in the end of the previous consolidated accounting year was utilized, as it was accepted that there was no
significant change in the situation of accrued temporally differences from the end of the previous consolidated
accounting year.
[2] Accounting procedures unique for preparation of quarterly consolidated financial statements: N/A(3) Overview of changes in accounting principles, procedures, and disclosure for preparation[1] Change in accounting principles(Application of Revised Accounting Standard for Equity Method of Accounting for Investments)
Effective from the first quarter of fiscal year 2010, the Company has applied the Revised Accounting Standard
for Equity Method of Accounting for Investments (Accounting and Standards Board of Japan (ASBJ) Statement
No. 16, issued March 10, 2008) and the Practical Solution on Unification of Accounting Policies Applied to
Associates Accounted for Using the Equity Method (Practical Issues Task Force (PITF) No. 24, issued March
10, 2008). There is no impact on profit and loss regarding to this change.
(Application of Accounting Standard for Asset Retirement Obligations)
Effective from the first quarter of fiscal year 2010, the Company has applied the Accounting Standard for
Asset Retirement Obligations (ASBJ Statement No. 18, issued on March 31, 2008) and Guidance on
Accounting Standard for Asset Retirement Obligations (ASBJ Guidance No. 21, issued on March 31, 2008).
The impact of this change was to reduce both operating income and ordinary income by 5 million yen andincome before income taxes by 93 million yen.
(Application of Accounting Standards for Business Combinations)
Effective from the first quarter of fiscal year 2010, the Company has applied Accounting Standard forBusiness Combinations (ASBJ Statement No. 21), issued on December 26, 2008; Accounting Standard forConsolidated Financial Statements (ASBJ Statement No. 22), issued on December 26, 2008; Partial
Amendments to Accounting Standard for Research and Development Costs(ASBJ Statement No. 23), issued
on December 26, 2008; Revised Accounting Standard for Business Divestitures (ASBJ Statement No. 7,
revised 2008), issued on December 26, 2008; Revised Accounting Standard for Equity Method of Accounting
for Investments (ASBJ Standard No. 16, revised 2008), issued on December 26, 2008; and Revised Guidanceon Accounting Standard for Business Combinations and Accounting Standard for Business Divestures (ASBJ
Guidance No. 10, revised 2008),issued on December 26, 2008. There is no impact on profit and loss regarding
to this change.
[2] Change in accounting principles(Overview of changes in significant consolidated subsidiaries)
As a result of the application of the Cabinet Office Ordinance Partially Revising Regulation on Terminology,
Forms and Preparation of Financial Statements (Cabinet Office Ordinance No.5, March 24, 2009) based on the
Accounting Standard for Consolidated Financial Statements (ASJB Statements No. 22 of December 26, 2008),
the item “Income before minority interests” is included in the financial statements in the current six months
period.

-5-

3. Consolidated Financial Statements(1) [ Consolidated Balance Sheets ](Amount: million yen)

As of
September 30, 2010
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery, equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Guarantee deposits
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
March 31, 2010

55,08058,88641,005
7,565
10,914
3,353
7,395
(470)
183,730

59,26656,30338,503
6,192
10,008
3,149
6,937
(432)
179,928

110,282(58,908)
51,373130,115(87,752)
42,362
19,811
1,469
(302)
1,166
10,396
26,633(21,309)5,324
130,434

107,011(56,495)
50,515
117,534(81,395)
36,13819,766
1,393
(173)
1,220
11,99225,032(20,456)
4,575
124,208

11,781143
1,925
13,849

561
78
1,736
2,376

52,022
594
3,989
3,587
(3,138)57,054
201,339
385,070

72,875
334
4,071
2,788
(3,186)76,883
203,468
383,396

(Amount: million yen)

As of
September 30, 2010
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bonuses
Income taxes payable
Provision for bonuses
Provision for directors' bonuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total valuation and translation adjustments
Minority interests
Total net assets
Total liabilities and net assets

-7-

As of
March 31, 2010

32,813
68,106
10,050
335
4,437
3,012
2,035
150
1,954
4,688
9,421
137,005

29,20364,442
10,00010,160
318
5,792
204
4,932
1,758
23
1,954
3,869
5,543
138,204

28,00028,00015,00015,00079,588
1,072
6,264
2,073
615
170
1,693
134,478
271,483

72,839
1,098
7,771
1,972
614
170
1,655
129,121267,325

28,66329,97247,818(863)
105,590

28,66329,972
47,219(862)
104,993

12,685(6,723)
5,961
2,034
113,586
385,070

15,024(5,708)9,316
1,761
116,070
383,396(2) [ Consolidated Statements of Income ](Amount: million yen)Six months ended
September 30, 2009
87,43561,851
25,584
16,3229,261

Six months ended
September 30, 2010
94,64065,92728,713
19,682
9,031

105
326
355
787

160
346
239
746

1,110
148
942
758
89
3,050
6,999

1,179
2,785
155
186
4,307
5,470

23
193
109
32
358

14
122
300
106
543

23
444
190

75
104
-

Loss on adjustment for changes of accounting
standard for asset retirement obligations

-

88

Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

128
786
6,571
3,371
(484)
2,887
189
3,494

132
401
5,612
2,707
203
2,911
2,700
231
2,469

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Depreciation
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Compensation income
Surrender value of insurance
Licensed dealership charges
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Abnormal manufacturing cost
Corresponding loss to compensation income-8-(3) [ Consolidated Statements of Cash Flows ](Amount: million yen)Six months ended
September 30, 2009
Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Proceeds from governmental subsidies
for investment in property and equipment
Net decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (used in) investment activities-9-

Six months ended
September 30, 2010

6,571
8,466
146
758
53
(432)
1,110
55
(5,429)
(474)
2,601
493
(434)
(156)
13,330587(1,133)353(250)(2,018)
10,868

5,612
9,319
67
1,142
155
42
(506)
1,179
285
(2,290)(4,019)
4,532
74
(924)
(7)
14,662504(1,172)467(223)(4,654)
9,583(1,349)1,413(1)(19,335)
58(1,390)1,990(2,820)(9,214)
40

202

25

539
0
2
(18,471)

(294)
(23)
7
(997)
(12,676)

(Amount: million yen)Six months ended
September 30, 2009
Net cash provided by (used in) financing activities
Net increase (decrease) in short-term loans payable
Increase (decrease) in commercial papers
Proceeds from long-term loans payable
Repayment of long-term loans payable
Proceeds form issuance of bonds
Redemption of bonds
Decrease (increase) in treasury stock
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid for minority shareholders
Other payments
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 10 -

Six months ended
September 30, 2010

7,874
10,0007,800(9,337)
2,982(16,505)
(10)
(65)
(2)
(2)
(21)
2,713
(642)
(5,532)45,352(223)(10,000)
20,809(10,157)
(110)
(1)
(179)
(1,864)(3)(6)(1,735)(326)(5,154)56,188-

1,595

39,81952,628

(4) Notes related to going concern
N/A(5) Segment information<Segment information by business category>
Six months ended September 30, 2009

(Millions of yen)

MedicalEquipment

Pharmaceutical

Glass &
Materials(1)Sales to third parties

54,881

28,023

4,198

331(2)Inter-segment sales
and transfers

-

0

1,960

54,881

28,024

9,151

2,503

Eliminations/Corporate

Consolidated

87,435-87,43546

2,007(2,007)

-

6,159

378

89,442(2,007)87,435884

29

12,569(3,307)

9,261

Other

Total

Net sales

Total
Operating income

Notes: 1. Classification of business categories and main products in each business category
Business categories are classified based on the proximity in terms of purposes andmanners of usage of the products in the market.
Main products belonging to each business category are as follows:Business
category
MedicalEquipment

Main products and commodities
Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets,
etc.

Pharmaceutical

Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysis
solution, and circulatory drugs, etc.

Glass & Materials

Glass for pharmaceutical containers, glass for thermos bottles, glass forlighting purposes, stoppers for plastic containers and rubber stoppers, etc.

Other

Machinery for manufacture of medical equipment and real estate rental
income, etc.

- 11 -

<Segment information by geographical area>
Six months ended September 30, 2009
Japan

(Millions of yen)

America

Asia

EuropeTotal

Eliminations/Corporate

Consolidated

Net sales(1) Sales to third parties

68,679

8,868

6,308

3,578

87,435-87,435(2) Inter-segment sales
and transfers

14,131

320

2

7,436

21,891(21,891)-

Total

82,810

9,189

6,310

11,015

109,326(21,891)

87,435

Operating income (loss)

11,749

(23)

55

1,114

12,896(3,634)

9,261

Notes:

1.

Classification of countries or areas is based on geographical proximity.

2.

The major countries included in each geographical area are as follows:
America……..
Europe………
Asia………….

The United States of America and Brazil
Belgium
China, Thailand and Singapore<Overseas sales>
Six months ended September 30, 2009

1. Overseas sales(Millions of yen)

America

Europe

Asia

Total

14,377

10,605

5,243

30,226

2. Consolidated net sales
3. Percentage of overseas sales toconsolidated net sales (%)

Notes:

87,435

16.5％

12.1%

6.0％

34.6％

1.

Overseas sales represent those of the Company and the consolidated subsidiaries to countries
and areas outside of Japan.

2.

Classification of countries or areas is based on geographical proximity.

3.

The major countries included in each geographical area are as follows:
America ·······
Europe·········
Asia ·············The United States of America, Canada and Brazil
Belgium, Denmark and Germany
China, India, Indonesia, Taiwan and Thailand- 12 -

<Segment information>
1. Outline of reportable operating segments
The reportable operating segments are components of an entity for which separate financial information isavailable and evaluated regularly by the board of director in determining the allocation of management
resources and in assessing performance.
We currently operate our business on a stand-alone basis with the divisional organization and evaluate theperformance of sales and manufacture of each division regardless of their products. Accordingly, we divide ouroperations into 3 reportable operating segments on the basis of its main products: Medical, Pharmaceuticals
and Glass & Materials.
*MedicalDomestic division sells injection- and infusion-related products, artificial organ-related products,
highly functional products, dialysis-related products and diabetic-related products.
In the international division, head office plays the center role and place overseas sales andmanufacturing base for medical equipment and sales injection- and infusion-related products,
artificial organ-related products and diabetic-related products.
*Pharmaceutical
Mainly, domestic subsidiaries sell and manufacture injectable drug, oral drugs and products bycontract manufacturing like combination products (Kit injectable).
*Glass & Materials
In the field of glass for pharmaceutical purposes, we sell glass for glass tube, glass forampoule. In the field of glass & materials products, we sell glass for thermos bottles and glass forlighting purpose. In addition, we sell container for combination products and undertake thecontract sales of pharmaceuticals related to the container for combination products frompharmaceutical company.
2. Sales and profit by reportable operating segments
Six months ended September 30, 2010

(Millions of yen)Segment

Medical

Other
Note.1

Total

Adjustment
Note.2

Consolidated
statements ofincomeNote.3

Pharmaceutical

Glass &
Materials

Total

18,80811,754

94,428212

94,640-94,640

8,714

1,936

10,75919

10,778(10,778)-

Net sales(1)Sales to third parties 63,866(2)Inter-segment sales
108
and transfers
Total

63,974

27,522

13,691

105,187

231

105,419(10,778)

94,640

Segment profit

9,440

1,021

1,294

11,75644

11,801(2,770)9,031

Notes:

1.
2.

3.

“Other” is the business segment which is not included in the reporting segment and consist ofreal estate income and sales by headquarter.
Adjustment for the segment profit of (2,770) million yen includes elimination of inter-segment
transaction of 302 million yen and corporate cost of (3,073) million yen. Corporate cost consisted
primarily of sales, general and administrative expenses and research and development costwhich do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

3. Information on goodwill by reportable operating segments(Significant variation in the amount of goodwill)
We included the Nipro Diagnostics, Inc. and other 3 companies in the scope of consolidation.
The regarding increase in the amount of goodwill was 11,394 million yen compared with the endof the previous year.

- 13 -

(Additional information)
Effective from the first quarter ended June 30, 2010, we have applied the revised AccountingStandard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Statement
No. 17, issued March 27, 2009) and Guidance on Accounting Standard for Disclosures about
Segments of an Enterprise and Related Information (ASBJ Guidance No. 20, issued March 21, 2008).

(6)Notes to statements of shareholders’ equity, if having significant variation
N/A- 14 -